The independent source for health policy research, polling, and news.
161-180 of 707 results
This year鈥檚 JPMorgan confab, the first since covid鈥檚 chilling effect on such gatherings, was full of energy and enthusiasm. But it was also marked by questions about the future of health care investment.
California Attorney General Rob Bonta is taking three major drugmakers and three distributors to court, alleging the companies illegally raised prices at the expense of diabetes patients.
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Colorado has joined Florida, New Hampshire, and New Mexico in seeking federal permission to import prescription drugs from Canada. President Joe Biden endorsed the approach in his 2020 campaign but has yet to approve any state plan.
Sen. Raphael Warnock鈥檚 re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.
Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.
Lupron, a drug patented half a century ago, treats advanced prostate cancer. It鈥檚 sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals 鈥 which may pay nearly as little for the drug 鈥 charging so much more to administer it?
Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency鈥檚 reviews have gone much faster 鈥 perhaps too fast.
Congress has once again decided not to decide how to fund the federal government in time for the start of the fiscal year, racing toward a midnight Sept. 30 deadline to pass a stopgap bill that would keep the lights on for two more months. However, it does appear the FDA鈥檚 program that gets drugmakers to help fund some of the agency鈥檚 review staff will be renewed in time to stop pink slips from being sent. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Victoria Knight of Axios join KHN鈥檚 Julie Rovner to discuss these topics and more. Also this week, Rovner interviews filmmaker Cynthia Lowen, whose new documentary, 鈥淏attleground,鈥 explores how anti-abortion forces played the long game to overturn Roe v. Wade.
Texas is at least the 12th state to settle with St. Louis-based Centene Corp. over allegations that it overcharged Medicaid prescription drug programs.
In this episode, Julie Rovner, chief Washington correspondent for KHN, guides listeners through decades of dealings between Congress and Big Pharma.
President Joe Biden has signed the Inflation Reduction Act and Congress is gone until after Labor Day. But the administration and lawmakers left lots of health policy achievements behind, including new rules to facilitate the sale of over-the-counter hearing aids and a potential reorganization of the Centers for Disease Control and Prevention. Anna Edney of Bloomberg News, Alice Miranda Ollstein of Politico, and Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, for extra credit, the panelists suggest their favorite health policy stories of the week they think you should read, too.
Inflation hasn鈥檛 hit Americans like this in decades. And families living with chronic diseases have little choice but to pay more for the medicine, supplies, and food they need to stay healthy.
The legislation, which the House is expected to pass Friday, would allow the federal government, for the first time, to negotiate the price of some drugs that Medicare buys. It also would extend the enhanced subsidies for people who buy insurance on the Affordable Care Act marketplaces.
For more than a century, the drug industry has issued dire warnings of plunging innovation whenever regulation reared its head. In general, the threat hasn鈥檛 materialized.
KHN chief Washington correspondent Julie Rovner discusses the Senate Democrats鈥 plans to let Medicare negotiate some drug prices, cap out-of-pocket drug costs for seniors, and fund enhanced subsides for ACA marketplace health plans.
The advocacy group American Commitment said empowering Medicare to negotiate drug prices would raid it of billions of dollars. Drug pricing experts say that that鈥檚 not the case and that such policies would instead reduce costs for the Medicare program and seniors.
Two things happened in Washington this week that were inevitable: President Joe Biden tested positive for covid-19, and the Senate agreed to move forward on a budget bill that includes only a sliver of what Biden hoped it would. Still, the bill to allow Medicare to negotiate some drug prices, cap out-of-pocket drug costs for seniors, and extend temporary subsidies for Affordable Care Act insurance premiums would represent a major step if Democrats can get it across the finish line. Meanwhile, abortion battles continue to escalate around the country, with Texas leading the way in restrictions. Shefali Luthra of The 19th, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dr. Jack Resneck Jr., the new president of the American Medical Association.
In addition to allowing federal officials to negotiate the price that Medicare pays for some drugs, the bill would cap annual out-of-pocket drug costs for Medicare beneficiaries at $2,000. But before Democrats can pass the bill under special rules that prevent Republicans from staging a filibuster, they must get approval from the Senate parliamentarian.
The FDA is using its power to regulate tobacco products 鈥 ordering the vaping device Juul off the market and announcing its intention to lower the amount of nicotine in cigarettes and other products. Meanwhile, the Supreme Court rules on Medicare and kidney dialysis, and Congress makes progress on legislation surrounding guns and mental health. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews KHN鈥檚 Noam N. Levey about the new KHN-NPR project on the growing impact of medical debt.
漏 2026 KFF